Adaptive Biotechnologies raised full-year 2026 revenue guidance for its minimal residual disease (MRD) business after reporting continued momentum in Q1. The company now expects MRD revenue between $260M and $270M, following 53% year-over-year growth in the segment and strong testing volume tied to its ClonoSeq assay. Adaptive reported record ClonoSeq test volume of 32,595 in the quarter, with blood-based testing representing 49% of clinical testing. The company also cited increased average selling price and expanding community-based ordering as contributors to growth. This update matters for investors tracking commercialization of MRD sequencing into routine care and for biotechs depending on MRD volumes as a proxy for clinical uptake and payer acceptance.